The global market for diagnostics in low-resource settings does not meet the needs of the millions of people living with HIV, TB, HPV, hepatitis and other diseases. Current testing coverage is low yet demand continues to grow sharply in the face of limited resources, highlighting the need for innovative approaches to enable robust, efficiently utilized testing capacity, and a healthy and secure market with competitive supply.

To help address the above needs, the Integrated Diagnostics Consortium (IDC) was formed in October 2017. The aim of the IDC is to enable better coordinated procurement and deployment of platform-based diagnostic technologies to support HIV, TB, HPV, and hepatitis testing scale-up. IDC stakeholders include major donors and procuring countries, implementing partners and technical agencies. Members include representatives of the governments of India, Kenya and South Africa, ASLM, the US Centers for Disease Control and Prevention, the Clinton Health Access Initiative, the Elizabeth Glaser Pediatric AIDS Foundation, Foundation for Innovative New Diagnostics (FIND), Médecins Sans Frontières, Management Sciences for Health, Solthis, Stop TB Partnership, The Global Fund, UNICEF, Unitaid, the US President’s Emergency Plan For AIDS Relief (OGAC, CDC, USAID) and the World Health Organization.

The Molecular Diagnostic Pricing Database

As part of the IDC, ASLM hosts the Molecular Diagnostic Pricing Database, led by the Clinton Health Access Initiative, with funding from Unitaid. The database initially focuses on automated molecular testing solutions offered to low- and middle-income countries (LMICs), to bring greater clarity and transparency to supplier pricing. The database will be updated biannually or when new information becomes available to reflect the latest changes in the market.

View the Molecular Diagnostic Pricing Database

Explore additional IDC resources here.